New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 12, 2014
08:27 EDTGENE, AGenetic Technologies says Agilent denied motion to dismiss patent suit
Genetic Technologies (GENE) announced that the United States District Court for the Northern District of California has last week issued an Order denying a motion brought by Agilent Technologies (A) to dismiss the patent infringement law suit brought against it by GTG. This action was initially brought by GTG against Agilent in 2011, in the District Court of Colorado, but was then moved at the request of Agilent to the District Court in the Northern District of California. GTG Acting CEO Tom Howitt repeated: “With the removal of what some potential licensees have apparently used as a reason to delay settlement discussions, we trust that good faith negotiations will now resume in earnest.”
News For GENE;A From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 9, 2015
15:23 EDTADako announces FDA approval of new lung test for cancer patients
Subscribe for More Information
October 6, 2015
07:23 EDTAAmerican Society of Human Genetics to hold annual meeting
Subscribe for More Information
October 5, 2015
05:29 EDTADako announces FDA approval of new companion diagnostic assay
Subscribe for More Information
October 2, 2015
15:57 EDTALabCorp to offer PD-L1 companion diagnostic
Subscribe for More Information
15:43 EDTAQuest Diagnostics introduces Dako's PD-L1 companion diagnostic for KEYTRUDA
Subscribe for More Information
15:25 EDTAAgilent's Dako confirms FDA approval of NSCLC diagnostic
Dako, an Agilent Technologies (A) company and a worldwide provider of cancer diagnostics, announced the FDA approval of a new companion diagnostic assay that can reveal whether a patient with advanced non-small cell lung cancer, or NSCLC, is likely to respond to a new form of treatment. The approval of PD-L1 IHC 22C3 pharmDx strengthens Dako's portfolio of companion diagnostics and the company's leadership position in developing and commercializing companion diagnostic products. Dako developed PD-L1 IHC 22C3 pharmDx in partnership with Merck (MRK), maker of the anti-PD-1 therapy Keytruda. The FDA approved PD-L1 IHC 22C3 pharmDx for use in the United States. Dako hopes to gain regulatory approval for the new diagnostic in Canada, Europe and other jurisdictions next year.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use